Sandrock Alfred 4

4 · Voyager Therapeutics, Inc. · Filed Feb 20, 2026

AI-generated summary of this filing

Updated Feb 20, 2026

Voyager (VYGR) CEO Alfred Sandrock Sells 11,732 Shares

What Happened

Alfred Sandrock, President & CEO and Director of Voyager Therapeutics (VYGR), sold 11,732 shares on Feb 18, 2026. The weighted-average sale price was $3.41 per share (prices ranged $3.35–$3.47), for total proceeds of about $40,006. The sale was a disposition (S) effected under a pre-existing durable automatic sale instruction to satisfy tax withholding related to RSUs that vested on Feb 17, 2026 — not a discretionary trade by the insider.

Key Details

Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (timely)
Shares sold: 11,732; weighted-average price: $3.41; price range: $3.35–$3.47
Total value reported: ~$40,006
Reason/footnote: Sell-to-cover automatic sale to satisfy tax withholding on vested restricted stock units (F1); sales occurred in multiple transactions (F2)
Shares owned after transaction: not specified in the provided filing excerpt
Exhibit included: 24.1 Limited Power of Attorney

Context

This was a routine sell-to-cover transaction tied to RSU vesting (tax withholding), which insiders commonly use and which does not necessarily indicate a change in sentiment. The filing indicates the sales were automatic and non-discretionary.

Form 4

Period: 2026-02-18

DirectorPresident and CEO

Transactions

Footnotes (2)

[F1]Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 17, 2026. The sales do not represent a discretionary trade by the reporting person.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.47, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Signature

/s/ Gregory L. Shiferman, as Attorney-in-Fact for Alfred Sandrock|2026-02-20

2 files